Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD) - LARVOL DELTA

HEMATOVAC: Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma (clinicaltrials.gov) - P4 | N=160 | Recruiting | Sponsor: Poitiers University Hospital | Trial completion date: Jun 2026 ➔ Nov 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia • RARA

A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4). (PubMed, Med) - P3 | "V116 exhibited immunogenicity and safety profiles that were consistent across three manufacturing lots."

Journal • P3 data • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

ENHANCING CARE FOR SICKLE CELL PATIENTS WITH A REAL-TIME LONGITUDINAL PATIENT TRACKING FACILITY WITHIN AN ELECTRONIC PATIENT RECORD SYSTEM (EHA 2025) - "Of 156 patients, 25 left our care between June 2021 and December 2024, resulting in two cohorts of n1=81 and n2=131.Quality indicators were selected based on the Standards for Clinical Care of Adults with SCD in the UK (Sickle Cell Society, 2018).Data collection included hydroxyurea (HU) usage, and urine testing for albumin creatinine clearance (ACR) at each time point. Vaccination records were obtained from primary care for 129 patients (67 (2021) and 114 (2024)).Completeness of vaccination uptake was measured through uptake of influenza (annual), the bexsero (any time) and the pneumovax (within 5 years) of the two timepoints.To assess hospital workload over this period, we recorded cumulative A&E attendances, haematology day unit attendance, clinic appointments, number of nights in hospital and admissions from A&E.A&E attendances rose from 34 (2021) to 62(2024), HDU attendance from 10 (2021) to 81 (2024), number of nights in hospital from 170 (2021) to 355..."

Clinical • Genetic Disorders • Hematological Disorders • Infectious Disease • Influenza • Respiratory Diseases • Sickle Cell Disease

RATES OF INFLUENZA AND PNEUMOCOCCAL VACCINATION AND CORRELATION WITH SURVIVAL IN MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SURVEY (EHA 2025) - "FV was performed in more than 70% of patients while less than a half of patients received PV, in one third of cases with a sub-optimal sequential administration of a polysaccharide vaccine (Pneumovax) followed by a pneumococcal conjugate vaccine (Prevnar13 or Prevnar20). In MM a response to PV is detectable, independently of preexisting hypogammaglobulinemia and possibly of treatment-induced immunodepression, even if a drop in the serum response overtime suggests the need of a dedicated schedule with a multidisciplinary approach, especially in the setting of RRMM patients."

Clinical • Pneumococcal vaccines • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Oncology • Pneumococcal Infections • Psychiatry • Respiratory Diseases

Epidemiological Impact of Increasing Vaccination Coverage Rate and Re-Vaccination on Pneumococcal Disease in Older Adults in Germany. (PubMed, Vaccines (Basel)) - "Increasing the vaccination coverage rate to 60% and strategically revaccinating previously PPSV23-vaccinated adults significantly enhanced the effectiveness of pneumococcal vaccines, with V116 showing greater overall reductions in disease incidence compared to PCV20 or PPSV23."

Journal • Geriatric Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - P2 | N=49 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ May 2026 | Trial primary completion date: Dec 2024 ➔ Jul 2024

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10). (PubMed, Vaccines (Basel)) - P3 | "The safety profile of V116 was comparable to that of PPSV23. In regions with established vaccination programs, V116 could broaden the serotype coverage for residual pneumococcal disease in adults."

Journal • P3 data • Infectious Disease • Pediatrics • Pneumococcal Infections

3-Year-Old Female with Specific Antibody Deficiency and 9p Duplication Treated with Replacement Immunoglobulin (CIS 2025) - "The patient had 2/23 Streptococcus pneumoniae titers protective above 1.3 mcg/mL after initial Prevnar 13 administration and then only 4/14 S. pneumoniae titers protective above 1.3 mcg/mL after Pneumovax 23 booster...Despite initial treatment with prophylactic azithromycin and revaccination for S. pneumoniae, the patient developed COVID-19 pneumonia and rhino enterovirus with severe respiratory failure requiring two separate hospitalizations over three months and no significant improvement in strep pneumoniae titers. Subcutaneous immunoglobulin replacement therapy was initiated, and she has been on biweekly subcutaneous immunoglobulin replacement for four months with symptomatic improvement and no further infectious diagnosis.This case highlights that patients with 9p duplication and other rare genetic disorders are at risk for immune dysfunction and can benefit from replacement immunoglobulin. Patients with rare genetic disorders that have not been previously linked to..."

Cerebral Palsy • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases • Sinusitis • Tetanus • IL2

Recurrent Sinopulmonary Infections in an 8-Year-Old Boy with Cornelia de Lange Syndrome (CIS 2025) - "Patient was immune to varicella, hepatitis B, tetanus, and diphtheria post-vaccination but only had 1/23 strep pneumoniae titers above 1.3 ug/mL and only 4/23 above 0.5 ug/mL after primary Prevnar 13 series...Patient given booster vaccination with Pneumovax and had improvement in strep pneumoniae titers to 16/23 protective above 1.3 ug/mL and decreased clinical infections. The cohesin protein complex plays a significant role in the immune system, and altered expression of immune-related genes in patients with CdLS may explain the varying degrees of immunodeficiency observed in these individuals. Although no specific immune defect has been universally identified in CdLS, and there are no established guidelines for managing immune issues or vaccination in this population, it is important to conduct clinical immunologic evaluations for CdLS patients who experience recurrent infections as booster vaccinations can significantly improve these patients' quality of life."

Developmental Disorders • Gastrointestinal Disorder • Genetic Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Mental Retardation • Ophthalmology • Otorhinolaryngology • Pneumonia • Respiratory Diseases • Tetanus • Varicella Zoster • CD4 • CD8 • NIPBL

The Value of Pneumovax Testing in the Prevnar 20 Era (CIS 2025) - "Even in subjects who have previously received PCV13 or PCV20, there is still diagnostic utility in administration of PPSV23 and evaluation of the response to the unique serotypes as a means of assessing anti-polysaccharide antibody responses."

Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency

Economic evaluation of PCV21 in vaccine-naïve adults aged 19-64 years with underlying medical conditions in the United States. (PubMed, J Med Econ) - "The analysis indicated that the V116 strategy prevented a substantial number of cases and deaths compared to the PCV20 or PCV15 + PPSV23 strategies among vaccine-naive AR/HR adults aged 19-49 and 50-64 years...Deterministic and probabilistic sensitivity analyses confirmed the robustness of these findings, with over 95% of simulations yielding cost-saving results and all estimated ICERs remaining below $10,000/QALY gained. The findings suggest that the use of PCV21 (Capvaxive™) in adults aged 19-64 years with underlying medical conditions in the US can prevent a significant number of pneumococcal disease cases and deaths while demonstrating favorable economic outcomes across various scenarios."

HEOR • Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Clinical Trial of PCV24 in Adults (clinicaltrials.gov) - P1 | N=170 | Completed | Sponsor: Sinovac Life Sciences Co., Ltd. | Trial primary completion date: Feb 2025 ➔ Aug 2024 | Recruiting ➔ Completed

Trial completion • Trial primary completion date • Infectious Disease • Pneumococcal Infections

STRIDE-13: A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (clinicaltrials.gov) - P3 | N=882 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (clinicaltrials.gov) - P3 | N=1484 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. (PubMed, Vaccines (Basel)) - P3 | "Co-administration of mRNA-1273 with PPSV23 or PCV15 in healthy adults ≥50 years of age was immunogenic and well tolerated."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Clinical Audit of Vaccination in Patients Living with Inflammatory Arthritis and Receiving Specialty Medications (CRA-AHPA 2025) - "Vaccinations against influenza, COVID-19, pneumonia (Prevnar 13/20, Pneumovax-23), and shingles (Shingrix) were reviewed. In this audit we found increased vaccination rates in the nurse clinic and among patients > 65 years old. High vaccination rates observed in the nurse clinic likely resulted from dedicated preventative health protocols, clinical stability of nurse clinic patients, and physician/nursing collaboration. Higher rates of >65 vaccination were likely due to increased vaccine receptiveness of older adults, public coverage and outreach programs (programs focusing on vaccination for patients in congregate living), clinic promotion efforts, and community (family physician, pharmacy) promotion of vaccination."

Clinical • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Rheumatology • Varicella Zoster

Insights into Insurance for Vaccine Coverage Patients on Specialty Medications (CRA-AHPA 2025) - "Full vaccination in the public insurance group were as follows: Influenza (81/132, 61.4%), COVID-19 (99/132, 75.0%), Prevnar 13 or 20 (75/132, 56.8%), Pneumovax 23 (106/132, 80.3%), and Shingrix (41/132, 31.1%). Overall, there were several important findings. The group with the highest vaccination rate across all categories were those possessing two or more insurance plans. Higher rates of influenza and Pneumovax 23 vaccination were seen in the public insurance group, but this is likely due to a majority of this group being older than 65 (age required for free Pneumovax coverage) and the general trend of increased influenza vaccination in older adults.[2] Prevnar and Shingrix vaccination rates were seemingly similar for public and private groups, however sub-group analysis presented an important finding."

Clinical • Reimbursement • US reimbursement • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Rheumatology • Varicella Zoster

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Utah | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma

Characterization of B Cell Subsets in Pediatric Patients with Humoral Immunodeficiency and Specific Antibody Deficiency (AAAAI-WAO 2025) - "Patients were diagnosed using established criteria, including a deficient immune response following vaccination with a polysaccharide antigen vaccine (Pneumovax)...Nine of the 13 patients (69%) had reduced numbers of switched memory B cells, with this abnormality observed in five out of six patients with genetic conditions (83%) and four out of seven without genetic conditions (57%). Conclusions Patients with specific antibody deficiency (SAD) can have decreased percentages and total numbers of class-switched memory B cells, abnormalities observed in both patients with and without genetic defects."

Clinical • Immunology • Metabolic Disorders • Pediatrics • Primary Immunodeficiency • CD27

Modelling the Epidemiological Impact of Different Adult Pneumococcal Vaccination Strategies in the United Kingdom. (PubMed, Infect Dis Ther) - "Projections revealed that in adults, V116 led to significantly greater reductions in IPD in the 65+ year-old population compared with PCV20 or PPSV23."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Time of day of vaccination does not influence antibody responses to pneumococcal and annual influenza vaccination in a cohort of healthy older adults. (PubMed, Vaccine) - "This study examined whether diurnal timing of a single dose of Pneumovax® (PPV-23) and seasonal influenza vaccine influenced antibody responses in 140 healthy adults over the age of 50...Although time of day did not influence vaccine immunogenicity in AM and PM cohorts, sustained cohort-wide antibody responses were demonstrated in an older population. Identifying 18 % of the total cohort exhibited suboptimal responses to pneumococcal or influenza vaccines underscores the imperative for enhancing vaccine efficacy within this age group to reduce morbidity and mortality."

Journal • Infectious Disease • Influenza • Pneumococcal Infections • Respiratory Diseases

Establishing a new human pneumococcal standard reference serum, MPRSS-01. (PubMed, mSphere) - "With the development of next-generation PCVs, a new S. pneumoniae reference serum standard was needed to include serotypes beyond the existing 24 in 007sp. In this study, antibody concentrations to 33 pneumococcal serotypes were assigned in a new Merck Pneumococcal Reference Serum Standard (MPRSS-01) using the pneumococcal electrochemiluminescence assay, enabling V116 to maintain the link to the historical human pneumococcal standard reference serum while utilizing the new human pneumococcal reference serum."

Biomarker • Clinical • Journal • Review • Infectious Disease • Pneumococcal Infections • Pneumonia

Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (PubMed, MMWR Morb Mortal Wkly Rep) - "Options included either 20-valent PCV (PCV20; Prevnar20; Wyeth Pharmaceuticals) or 21-valent PCV (PCV21; CAPVAXIVE; Merck Sharp & Dohme) alone or 15-valent PCV (PCV15; VAXNEUVANCE; Merck Sharp & Dohme) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax23; Merck Sharp & Dohme)...Recommendations for PCVs among adults aged 19-49 years with risk conditions and PCV13-vaccinated adults have not changed from previous recommendations. This report summarizes evidence considered for these recommendations and provides updated clinical guidance for use of PCV."

Journal • Infectious Disease • Pneumococcal Infections

MISP 60528 Pneumococcal Vaccination (clinicaltrials.gov) - P=N/A | N=45 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Transplantation

Anti-pneumococcal Vaccine Strategy in Patients with Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Seema Bhat | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Small Lymphocytic Lymphoma